TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02172586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Study: NCT01870674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04068688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Description: Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth coaching
Description: The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
Study: NCT03978884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50Mg Tab
Description: Take 1 tab daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET
Description: Take 1 tab daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
Description: Take 1 tab daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
Description: Take 1 tab daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
Description: Take 1 tab daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
Description: Take 1 tab daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Take 1 tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Take 1 tablet daily
Study: NCT05613699

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise - Social Media
Description: The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise - App
Description: Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise - closed to patients residence
Description: The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
Study: NCT00930865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: Tablets, Oral, 1 mg, Single Dose, 7 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: Tablets, Oral, 1 mg, Single Dose, 7 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg. Single Dose, 7 Days
Study: NCT00978783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passy Muir Valve
Description: The Passy Muir Valve was fixed on the tracheostomy tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive end expiratory pressure
Description: 5 cm H2O PEEP was adjusted
Study: NCT01184859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
Study: NCT00566956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrosalpinx needle aspiration to arm 1
Description: For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
Study: NCT00769535

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymorphisms of HSP70 and TNF promoter
Description: To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
Study: NCT00421824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine
Description: OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine
Description: XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
Study: NCT01184859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo melt tablet for sublingual administration
Study: NCT00930865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg. Single Dose, 7 Days
Study: NCT04041661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active tDCS plus gait training
Description: Participants in experimental group will accept Active tDCS which combined with treadmill

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS plus gait training
Description: Participants in control group will accept Sham tDCS which combined with treadmill
Study: NCT04037943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts 30 grams
Description: Roasted walnuts without salt or sugar.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts 60 grams
Description: Roasted walnuts without salt or sugar.
Study: NCT03683914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3Mg Vaginal Tablet
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal tablet
Description: 1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
Study: NCT00985634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LeGoo
Description: LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Vessel loops
Study: NCT05964556

Intervention type: OTHER
Intervention: Functional Movement Screen (FMS)
Description: FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.

Intervention type: OTHER
Intervention: Isokinetic Muscle Evulation of Knee Muscles
Description: The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D\&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
Study: NCT04701970

Intervention type: PROCEDURE
Group type: OTHER
Intervention: relining of mandibular complete denture
Description: Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
Study: NCT01967719

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS 2.2
Description: Single use of mTHS 2.2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS 2.2
Description: Single use of mTHS 2.2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS 2.2
Description: Single use of mTHS 2.2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS 2.2
Description: Single use of mTHS 2.2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCC
Description: Single use of subject's own mCC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCC
Description: Single use of subject's own mCC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NNS
Description: Single administration of 1 mg of nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NNS
Description: Single administration of 1 mg of nicotine
Study: NCT03562897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin-Viusid
Description: Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
Study: NCT03354897

Intervention type: DRUG
Group type: OTHER
Intervention: Torasemide 5Mg Tablet
Description: 16 weeks treatment
Study: NCT00651937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Collection of stem cells from blood collected either through CVC or from a vein in one arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Collection of stem cells from blood collected either through CVC or from a vein in one arm.
Study: NCT01314898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-03882845
Description: 3 mg PF-03882845, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PF-03882845
Description: 10 mg PF-03882845, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg PF-03882845
Description: 30 mg PF-03882845, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PF-03882845
Description: 100 mg PF-03882845, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 100 mg spironolactone, single oral dose
Study: NCT04739488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler training
Description: This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler training
Description: This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness.
Study: NCT00260676

Intervention type: PROCEDURE
Group type: OTHER
Intervention: change ventilation
Description: reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
Study: NCT01100892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Description: Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
Study: NCT00814632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: CC-10004 20 mg. twice a day for 12 weeks
Study: NCT03022110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound-guided Drainage
Description: Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound-guided Drainage
Description: Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
Study: NCT01304108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VTE-P Tollgate
Description: Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BLAZE Pop up
Description: Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No addition to the baseline system for care
Study: NCT02493881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative neuromonitoring
Description: NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative neuromonitoring
Description: NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
Study: NCT00549861

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Cardiac Magnetic Resonance study
Description: Cardiac MRI study
Study: NCT00729053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-2055
Description: immunostimulatory oligonucleotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-2055
Description: immunostimulatory oligonucleotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-2055
Description: immunostimulatory oligonucleotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-2055
Description: immunostimulatory oligonucleotide
Study: NCT03140878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGG
Description: LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
Study: NCT02168621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Section-wise scaling and root planing
Description: Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
Study: NCT04100239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
Study: NCT01580111

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.